Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin replacement therapy in septic shock
2018-001874-89Phase 3Terminated
- Sponsor
- Friedrich Schiller University Jena
- Start
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of albumin (human) in septic shock (2 arms), sponsored by Friedrich Schiller University Jena. Primary endpoint: 90-day all-cause mortality. Started Nov 2018; status: terminated.
02
Drugs
albumin (human)
03
Conditions
septic shock
Beyond the preview
Go deeper on 2018-001874-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001874-89.